Shijun Zhao

Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial

Yunpeng Yang, Jianya Zhou, Jianying Zhou et al. · The Lancet Respiratory Medicine · 2019 · 135 citations

Biomarker Analysis, Medicine, Pharmacology +8

Clinical characteristics and medical service utilization of lung cancer in China, 2005–2014: Overall design and results from a multicenter retrospective epidemiologic survey

Jufang Shi, Le Wang, Ning Wu et al. · Lung Cancer · 2018 · 132 citations

Medical Service Utilization, Oncology, Cancer Epidemiology +10

Ultrastructural Localisation of TGF-β Exposure in Dentine by Chemical Treatment

Shijun Zhao, Alastair J. Sloan, Peter E. Murray et al. · The Histochemical Journal · 2000 · 130 citations

Long-term follow-up of persistent pulmonary pure ground-glass nodules with deep learning–assisted nodule segmentation

Linlin Qi, Botong Wu, Wei Tang et al. · European Radiology · 2019 · 86 citations

Long-term Follow-up, Engineering, Medical Imaging +8

Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing

Yunpeng Yang, Jie Huang, Tao Wang et al. · Journal of Thoracic Oncology · 2021 · 43 citations · Full text